Shalini Subramaniam

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial nature.com/articles/s4301… In mCRPC, PSMA expression changes early with enzalutamide. In the ENZA-p trial, 68% of patients showed increased📈 PSMA PET SUV by day 15. This rise predicted shorter PSA progression-free survival with enzalutamide alone. However, adding 177Lu-PSMA-617 significantly improved outcomes in these patients, mitigating this adverse prognostic effect. Early PSMA SUV dynamics may serve as a predictive biomarker to guide combination therapy strategies in mCRPC. #ProstateCancer @drlouiseemmett @shalsubra @WeickhardtOnc @szetinglee1 @davcmed @thomashopemd @NarjessAyati @DrMHofman @SandhuShahneen @MartinStockler @Prof_IanD @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Access the full paper on PSMA-PET prognostic and predictive biomarkers in ENZAp with the link below: @ANZUPtrials @LancetOncology @TrialsCentre @MovemberAUS @PCFnews authors.elsevier.com/a/1lWie5EIIgTS…

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901) thelancet.com/journals/lanon… This prespecified substudy of the ENZA-p phase 2 trial evaluated whether baseline quantitative parameters from [⁶⁸Ga]Ga-PSMA-11 PET-CT could serve as prognostic or predictive biomarkers for patients with high-risk metastatic castration-resistant #ProstateCancer treated with enzalutamide alone or with [¹⁷⁷Lu]Lu-PSMA-617. Among 160 patients, baseline total PSMA tumor volume (PSMA-TTV) was found to be both prognostic for overall survival (OS) and predictive of benefit from the addition of [¹⁷⁷Lu]Lu-PSMA-617, with markedly longer OS in patients with lower PSMA-TTV. Conversely, baseline PSMA SUVmean did not predict outcomes. These findings suggest that PSMA-TTV may guide patient selection for [¹⁷⁷Lu]Lu-PSMA-617 therapy in this setting. @drlouiseemmett @shalsubra @AnthonyMJoshua @SandhuShahneen @WeickhardtOnc @szetinglee1 @JeffreyCGoh1 @DrDavePattison @NarjessAyati @DrMHofman @Prof_IanD @MartinStockler @OncoAlert @silkegillessen @AOmlin @nataliagandur @bavilima @yekeduz_emre

Third @LancetOncology paper to come out of the @ANZUPtrials #ENZAp #ProstateCancer #pcsm #ClinicalTrial - congratulations Louise Emmett and grateful thanks to all investigators, research teams, and of course the participants who have helped move the whole field ahead.

PSMA-PET total tumour volume is prognostic for overall survival in mCRPC. thelancet.com/journals/lanon… PSMA-PET value extends beyond selection for PSMA-RLT therapy in metastatic prostate cancer. urotoday.com/video-lectures… @ANZUPtrials @trialscentre @PCFnews @MovemberAUS

ENZA-P Just published at Lancet Oncology & Presented at #GU25 Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant #ProstateCancer buff.ly/41iv5oq In the ENZA-p trial, the addition of [177Lu]Lu-PSMA-617 to enzalutamide as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) resulted in improved overall survival (OS) and health-related quality of life (HRQOL) compared to enzalutamide alone. After a median follow-up of 34 months, patients receiving the combination treatment had a median OS of 34 months versus 26 months for those on enzalutamide alone, with a 45% reduction in the risk of death. HRQOL analyses favored the combination group, showing longer deterioration-free survival in both physical function and overall health, as well as less pain and fatigue until disease progression. Although the combination group experienced more xerostomia, adverse events were similar between the groups, with no treatment-related deaths. These findings support further evaluation of [177Lu]Lu-PSMA-617 in combination with androgen receptor inhibitors in future trials. @drlouiseemmett @shalsubra @AnthonyMJoshua @SandhuShahneen @WeickhardtOnc @szetinglee1 @JeffreyCGoh1 @DrCraigGedye @docpook @_vosko @pattibastick @MargaretMcJann1 @DrMHofman @Prof_IanD @MartinStockler

PSMA PET/CT or radioligand therapy mentioned 600 times in the @ASCO #GU25 prostate cancer abstracts (advanced and localized). I think around 1 in 5 of abstracts contain PSMA !! Amazing to see the uptake of this new technology over the last 10 years. ENZA-P was my highlight from the meeting - photo of the @ANZUPtrials team lead by @drlouiseemmett 👇

Being presented at @ASCO #GU25 ⬇️ Overall survival & QOL results from ENZA-p: [177Lu]Lu-PSMA-617 plus enzalutamide vs enzalutamide in metastatic castration-resistant #prostatecancer @drlouiseemmett @Prof_IanD @DrMHofman @MartinStockler @ANZUPtrials bit.ly/3ExZgPI

Congrats @ANZUPtrials #ENZAp study positive OS & QoL results presented by @drlouiseemmett @ASCSO #GU25 & published @TheLancet. @MovemberAUS @CancerAustralia @AstellasEurope #ARTnet @StVincentClinic @RoyMorganAus @Novartis @mimsoftware @GenesisCare @ANSTO @TrialsCentre @Prof_IanD

@nickymitchell Thanks so much, @nickymitchell 🙏🏾

Open to oncologists and trainees in New Zealand too! Closes next week, please fill in, your views are important

@DrChristinaTeng @MOGA_ORG @ausyoungoncs Thanks for completing and boosting, @DrChristinaTeng 🙏🏾

If you are an oncologist procrastinating on #SoMe this weekend, please consider using this time to help out a mate by completing this survey! #metastatic @MOGA_ORG @ausyoungoncs

Ping @DrAbhiPal @omalirp @DrChristinaTeng @DrBenKong @drprunellab @DKarikios @AOParsonson @DrLizConnolly @DrMelMoore @Mal_Itchins @AshMalalasekera @PeeySei @SandhuShahneen @TommyJohn00 - pls consider completing and sharing with colleagues! 🙏🏾

📣 Survey closing next week! If you haven’t already, please spare a moment to fill out. Thanks to the n=117👩‍⚕️👨‍⚕️from around the world who have completed! 🙌🏾 Please spread the word to your colleagues and trainees. 🔗 tinyurl.com/vfcwjmac

Why do the TheraP and VISION trials show different effects of Lu-177 PSMA on survival in advanced prostate cancer? It may be due to different comparison treatments. jamanetwork.com/journals/jaman… @MartinStockler @IanMarschner @DrMHofman @Prof_IanD @drlouiseemmett

Thanks to the 81 respondents who have completed the survey so far! 🙏🏾 Amazing response since going live a week ago. We'd love more perspectives from around the world so please share with your colleagues.

Sad to miss #WCLC24. Following from afar & continue to be amazed by the rapidly evolving lung cancer treatment landscape. Great progress for our patients’ long-term outcomes! For oncologists attending, please share your insights on the possibility of cure in metastatic cancer.

Is metastatic cancer curable? Seeking perspectives of oncologists and trainees who treat solid tumours. 🔗: tinyurl.com/vfcwjmac ⏱️: <15mins ✅: med/clin oncs from 🌎🌍🌏 @MOGA_ORG @ausyoungoncs @ANZUPtrials @TOGAANZ @OncoAlert #OncTwitter

Come work with the Medical Oncology Clinical Trials Unit at Bankstown-Lidcombe Hospital! We are an expanding trials unit serving a diverse multicultural community. Applications close 08/09/2024. iworkfor.nsw.gov.au/job/clinical-t…